| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cbdccf09d0919cc229954381a9a91e95 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N2800-52 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-5091
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-57426
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G01N33-942 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-473
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2015-06-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ebc97ae4b22e256e28f23daf2ee55eb4 |
| publicationDate |
2015-12-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2015197839-A1 |
| titleOfInvention |
Methods for treating, diagnosing and prognosing a haematological malignancy |
| abstract |
The invention relates to a serotonin receptor (5-HTR) inhibitorselected from the group consisting of a type 1 5-HTR inhibitorand a type 2 5-HTR inhibitorfor use in the prevention and/or treatment of a haematological malignancy. Additionallly, the invention relates to in vitromethods for the identificationor isolation of a malignant cell from a haematological malignancy or for diagnosing a haematological malignancy based on detecting the expression of type 1 5-HTR and/or type 2 5-HTR.Furthermore, the invention relates to in vitromethods for determining the prognosis, for monitoring the effect of a therapy or for designing a customized therapy in a subject suffering from a haematological malignancy based on determining the levels of type1 5-HTRand/or type 2 5-HTR. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018130685-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2018022823-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2771933-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11382867-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2789782-C1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2023122940-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017301934-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019141673-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11185542-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11446321-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3348266-A1 |
| priorityDate |
2014-06-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |